Cargando…

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

PURPOSE: Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer (NSCLC). Our objective was to compare the effectivene...

Descripción completa

Detalles Bibliográficos
Autores principales: Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Stathopoulos, J., Marosis, K., Michalopoulou, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180559/
https://www.ncbi.nlm.nih.gov/pubmed/21301848
http://dx.doi.org/10.1007/s00280-011-1572-5
_version_ 1782212657604984832
author Stathopoulos, G. P.
Antoniou, D.
Dimitroulis, J.
Stathopoulos, J.
Marosis, K.
Michalopoulou, P.
author_facet Stathopoulos, G. P.
Antoniou, D.
Dimitroulis, J.
Stathopoulos, J.
Marosis, K.
Michalopoulou, P.
author_sort Stathopoulos, G. P.
collection PubMed
description PURPOSE: Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer (NSCLC). Our objective was to compare the effectiveness of lipoplatin combined with paclitaxel versus cisplatin with paclitaxel in advanced non-squamous NSCLC. METHODS: During 2007–2010, 202 patients with non-squamous NSCLC (stage IIIB and IV) were recruited from the two participating institutions and divided into two arms: Arm A was treated with liposomal cisplatin 200 mg/m(2) combined with paclitaxel 135 mg/m(2) and Arm B with cisplatin 75 mg/m(2) in combination with paclitaxel 135 mg/m(2), repeated every 2 weeks. The number of cycles administered was 632 (Arm A) and 640 (Arm B), totaling 1,272. RESULTS: A partial response was achieved by 59.22% of Arm A patients versus 42.42% of Arm B, and the difference was statistically significant (P 0.036). The median survival time in months was 10 for Arm A and 8 for Arm B (P 0.1551). After 18 months, the number of surviving patients was double for Arm A versus Arm B. CONCLUSION: Liposomal cisplatin in combination with paclitaxel produces a statistically significantly higher response rate than cisplatin combined with paclitaxel in non-squamous NSCLC.
format Online
Article
Text
id pubmed-3180559
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-31805592011-10-04 Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer Stathopoulos, G. P. Antoniou, D. Dimitroulis, J. Stathopoulos, J. Marosis, K. Michalopoulou, P. Cancer Chemother Pharmacol Original Article PURPOSE: Liposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer (NSCLC). Our objective was to compare the effectiveness of lipoplatin combined with paclitaxel versus cisplatin with paclitaxel in advanced non-squamous NSCLC. METHODS: During 2007–2010, 202 patients with non-squamous NSCLC (stage IIIB and IV) were recruited from the two participating institutions and divided into two arms: Arm A was treated with liposomal cisplatin 200 mg/m(2) combined with paclitaxel 135 mg/m(2) and Arm B with cisplatin 75 mg/m(2) in combination with paclitaxel 135 mg/m(2), repeated every 2 weeks. The number of cycles administered was 632 (Arm A) and 640 (Arm B), totaling 1,272. RESULTS: A partial response was achieved by 59.22% of Arm A patients versus 42.42% of Arm B, and the difference was statistically significant (P 0.036). The median survival time in months was 10 for Arm A and 8 for Arm B (P 0.1551). After 18 months, the number of surviving patients was double for Arm A versus Arm B. CONCLUSION: Liposomal cisplatin in combination with paclitaxel produces a statistically significantly higher response rate than cisplatin combined with paclitaxel in non-squamous NSCLC. Springer-Verlag 2011-02-08 2011 /pmc/articles/PMC3180559/ /pubmed/21301848 http://dx.doi.org/10.1007/s00280-011-1572-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Stathopoulos, G. P.
Antoniou, D.
Dimitroulis, J.
Stathopoulos, J.
Marosis, K.
Michalopoulou, P.
Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
title Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
title_full Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
title_fullStr Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
title_full_unstemmed Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
title_short Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
title_sort comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180559/
https://www.ncbi.nlm.nih.gov/pubmed/21301848
http://dx.doi.org/10.1007/s00280-011-1572-5
work_keys_str_mv AT stathopoulosgp comparisonofliposomalcisplatinversuscisplatininnonsquamouscellnonsmallcelllungcancer
AT antonioud comparisonofliposomalcisplatinversuscisplatininnonsquamouscellnonsmallcelllungcancer
AT dimitroulisj comparisonofliposomalcisplatinversuscisplatininnonsquamouscellnonsmallcelllungcancer
AT stathopoulosj comparisonofliposomalcisplatinversuscisplatininnonsquamouscellnonsmallcelllungcancer
AT marosisk comparisonofliposomalcisplatinversuscisplatininnonsquamouscellnonsmallcelllungcancer
AT michalopouloup comparisonofliposomalcisplatinversuscisplatininnonsquamouscellnonsmallcelllungcancer